Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to investors at the Proactive One2One Virtual Event. Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. It has Europe's only 24-bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London.
Open Orphan PLC - Proactive One2One Virtual Event
Quick facts: Open Orphan PLC
Price: 24.4 GBX
Market Cap: £175.13 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE